Skip to content
Screener

Operating Income at other companies

Cardinal Health logo
Cardinal HealthCAH
$509M-30.3%
McKesson logo
McKessonMCK
$1.32B+27.3%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$40.46M+191%
Cencora logo
CencoraCOR
$1.12B+29.1%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$336.6M+702%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
-$125.1M-7,919%

Segments

By segment

See full
Affordable Medicines$123.08M+20.2%
AvKARE$9.34M-48.6%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Restructuring and other charges5541,0241,2041,595
Charges (credit) related to legal matters, net8,057(390)8,751(390)
Other operating income(1,298)(8,239)(5,122)
Operating income129,769111,372271,541211,719
Other (expense) income:
Interest expense, net(55,043)(65,101)(108,404)(122,040)
Foreign exchange (loss) gain, net(1,950)8,256(9,750)12,503
Loss on refinancing(3,510)

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s operating income?
Amneal Pharmaceuticals, Inc. (AMRX) reported operating income of $129.77M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s operating income changed year-over-year?
Amneal Pharmaceuticals, Inc.'s operating income increased by 16.5% year-over-year, from $111.37M to $129.77M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s operating income?
Over 3 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s operating income has grown at a 37.2% compound annual growth rate (CAGR), from $152.72M to $394.1M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Amneal Pharmaceuticals, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude